Table 3.
Proportion of trials that selected each dose level as the final MTD out of 1000 trials for a given scenario; R(di) denotes true DLT rates. CRMB is the original Bayesian CRM; CRML2, CRML3, CRML4 and CRML5 use pseudodata and the approach described in Section 4.2 with skeletons s2, s3, s4, s5 respectively.
| Levels | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|
| R(di) | 0.00 | 0.00 | 0.03 | 0.05 | 0.11 | 0.22 |
| CRMB | 0.00 | 0.00 | 0.00 | 0.07 | 0.60 | 0.32 |
| CRML2 | 0.00 | 0.00 | 0.00 | 0.06 | 0.39 | 0.54 |
| CRML3 | 0.00 | 0.00 | 0.00 | 0.05 | 0.30 | 0.65 |
| CRML4 | 0.00 | 0.00 | 0.00 | 0.07 | 0.39 | 0.55 |
| CRML5 | 0.00 | 0.00 | 0.00 | 0.05 | 0.30 | 0.65 |
| R(di) | 0.00 | 0.00 | 0.03 | 0.05 | 0.06 | 0.22 |
| CRMB | 0.00 | 0.00 | 0.00 | 0.05 | 0.44 | 0.52 |
| CRML2 | 0.00 | 0.00 | 0.00 | 0.04 | 0.28 | 0.68 |
| CRML3 | 0.00 | 0.00 | 0.00 | 0.03 | 0.22 | 0.75 |
| CRML4 | 0.00 | 0.00 | 0.00 | 0.04 | 0.28 | 0.68 |
| CRML5 | 0.00 | 0.00 | 0.00 | 0.03 | 0.22 | 0.75 |
| R(di) | 0.00 | 0.00 | 0.03 | 0.05 | 0.10 | 0.30 |
| CRMB | 0.00 | 0.00 | 0.00 | 0.06 | 0.68 | 0.26 |
| CRML2 | 0.00 | 0.00 | 0.00 | 0.06 | 0.51 | 0.43 |
| CRML3 | 0.00 | 0.00 | 0.00 | 0.06 | 0.42 | 0.52 |
| CRML4 | 0.00 | 0.00 | 0.00 | 0.06 | 0.50 | 0.44 |
| CRML5 | 0.00 | 0.00 | 0.00 | 0.05 | 0.44 | 0.51 |
| R(di) | 0.00 | 0.00 | 0.03 | 0.05 | 0.10 | 0.50 |
| CRMB | 0.00 | 0.00 | 0.00 | 0.06 | 0.83 | 0.10 |
| CRML2 | 0.00 | 0.00 | 0.00 | 0.06 | 0.76 | 0.18 |
| CRML3 | 0.00 | 0.00 | 0.00 | 0.07 | 0.70 | 0.23 |
| CRML4 | 0.00 | 0.00 | 0.00 | 0.06 | 0.75 | 0.19 |
| CRML5 | 0.00 | 0.00 | 0.00 | 0.07 | 0.71 | 0.22 |
| R(di) | 0.20 | 0.90 | 0.90 | 0.90 | 0.90 | 0.90 |
| CRMB | 0.96 | 4.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| CRML2 | 0.96 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| CRML3 | 0.99 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| CRML4 | 0.96 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| CRML5 | 0.99 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |